DDInter1853 DDInter612
Tretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of [vitamin A] (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is normally found at very low concentrations, approximately 4 to 14 nmol/L. Tretinoin exhibits anti-inflammatory, antineoplastic, antioxidant, and free radical-scavenging activities. It has been used in dermatology for many years to treat various skin conditions ranging from acne to wrinkles [A257474,A258185] and activates nuclear receptors to regulate epithelial cell growth and differentiation.[A257474,A257629,A257609] Tretinoin is given orally to treat acute promyelocytic leukemia and topically to treat skin conditions such as acne.[L45389,L34869,L45384]
Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed that this agent is a potent inhibitor of both forms. Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.
Tretinoin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Duvelisib
Tretinoin {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Duvelisib
Tretinoin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Cabazitaxel
Cabazitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Tretinoin {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Tretinoin {u} (Compound) causes {v} (Side Effect) Insomnia
Insomnia {u} (Side Effect) is caused by {v} (Compound) Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Duvelisib
Tretinoin {u} (Compound) causes {v} (Side Effect) Insomnia
Insomnia {u} (Side Effect) is caused by {v} (Compound) Simvastatin
Simvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Tretinoin {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Sunitinib
Sunitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duvelisib
Tretinoin {u} (Compound) downregulates {v} (Gene) TIMM9
TIMM9 {u} (Gene) is downregulated by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Duvelisib
Tretinoin {u} (Compound) causes {v} (Side Effect) Chest discomfort
Chest discomfort {u} (Side Effect) is caused by {v} (Compound) Bosutinib
Bosutinib {u} may lead to a major life threatening interaction when taken with {v} Duvelisib
Tretinoin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Clarithromycin {u} may lead to a major life threatening interaction when taken with {v} Duvelisib
Tretinoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Tretinoin (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Tretinoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cabazitaxel (Compound) and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Tretinoin (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Tretinoin (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Sibutramine (Compound) and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Duvelisib
Tretinoin (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Simvastatin (Compound) and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Tretinoin (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Sunitinib (Compound) and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Tretinoin (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Duvelisib
Tretinoin (Compound) causes Chest discomfort (Side Effect) and Chest discomfort (Side Effect) is caused by Bosutinib (Compound) and Bosutinib may lead to a major life threatening interaction when taken with Duvelisib
Tretinoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may lead to a major life threatening interaction when taken with Duvelisib